PMID- 37587984
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230818
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Efficacy and safety of Danggui Niantong Decoction in patients with gout: a 
      systematic review and meta-analysis.
PG  - 1168863
LID - 10.3389/fphar.2023.1168863 [doi]
LID - 1168863
AB  - Background: This study aims to evaluate the efficacy and safety of Danggui 
      Niantong Decoction (DGNT) systematically on gout treating. Methods: This study 
      was registered in PROSPERO, and the registration number was CRD42021271607. By 
      the end of December, 2022, literature research was conducted among eight 
      electronic databases. Main results of this study were blood uric acid (BUA) and 
      Creactive protein (CRP). Secondary outcomes were erythrocyte sedimentation rate 
      (ESR), serum creatinine (Scr), urinary protein quantified at 24 h (Upro), and 
      interleukin-8 (IL-8). Study screening, data collection, as well as quality 
      assessment were performed by two reviewers independently, and analysis was 
      completed using Stata (SE15.0) and Review Manager (5.4). Results: A total number 
      of 13 studies were included in our meta-analysis (n = 1,094 participants). 
      Results showed DGNT combined with conventional western medicine (CWM) was more 
      effective than WM alone in BUA (weighted mean differences (WMD) = -3.49, 95% 
      confidence interval (CI) [-50.36, -32.59], p = 0.000), CRP (WMD = -41.48, 95% CI 
      [-4.32, -2.66], p = 0.017), ESR (WMD = -6.23, 95% CI [-9.28, -3.17], p = 0.019), 
      Scr (WMD = -18.64, 95% CI [-23.09, -14.19], p = 0.001), Upro (WMD = -0.72, 95% CI 
      [-0.91, -0.53], p = 0.000), and IL-8 (WMD = -4.77, 95% CI [-11.48, 1.94], p = 
      0.000). None of the adverse effects noted were severe, and no life-threatening 
      event was reported. Conclusion: This study shows that DGNT combined with CWM 
      seems to have an effective clinical therapeutic potential. In addition, it also 
      provides a scientific basis for better clinical application of DGNT in the 
      future. Systematic Review Registration: 
      https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021271607; 
      Identifier: PROSPERO, CRD42021271607.
CI  - Copyright (c) 2023 Peng, Tian, Jin, Wang, Xie, Zheng, Liu, Cao, Zhang and Zhang.
FAU - Peng, Sihan
AU  - Peng S
AD  - TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of 
      Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Tian, Jing
AU  - Tian J
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Jin, Luchang
AU  - Jin L
AD  - Huaxi Securities Co., Ltd., Chengdu, Sichuan, China.
FAU - Wang, Hongyan
AU  - Wang H
AD  - Sichuan Nursing Vocational College, Chengdu, Sichuan, China.
FAU - Xie, Chunguang
AU  - Xie C
AD  - TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of 
      Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zheng, Jie
AU  - Zheng J
AD  - College of Basic Medical Sciences, Air Force Medical University, Xian, Shaanxi, 
      China.
FAU - Liu, Linfeng
AU  - Liu L
AD  - Sichuan Nursing Vocational College, Chengdu, Sichuan, China.
FAU - Cao, Jun
AU  - Cao J
AD  - Sichuan Nursing Vocational College, Chengdu, Sichuan, China.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Sichuan Nursing Vocational College, Chengdu, Sichuan, China.
FAU - Zhang, Xiangeng
AU  - Zhang X
AD  - Sichuan Nursing Vocational College, Chengdu, Sichuan, China.
LA  - eng
PT  - Systematic Review
DEP - 20230726
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10426740
OTO - NOTNLM
OT  - Danggui Niantong Decoction
OT  - efficacy
OT  - gout
OT  - meta-analysis
OT  - safety
OT  - systematic review
COIS- LJ was employed by the Company Huaxi Securities Co., Ltd. The remaining authors 
      declare that the research was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/08/17 06:43
MHDA- 2023/08/17 06:44
PMCR- 2023/07/26
CRDT- 2023/08/17 03:57
PHST- 2023/02/18 00:00 [received]
PHST- 2023/07/11 00:00 [accepted]
PHST- 2023/08/17 06:44 [medline]
PHST- 2023/08/17 06:43 [pubmed]
PHST- 2023/08/17 03:57 [entrez]
PHST- 2023/07/26 00:00 [pmc-release]
AID - 1168863 [pii]
AID - 10.3389/fphar.2023.1168863 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Jul 26;14:1168863. doi: 10.3389/fphar.2023.1168863. 
      eCollection 2023.